Abel Hall LLC
LENZ icon

Abel Hall LLC’s LENZ Therapeutics LENZ Stock Holding History

Abel Hall LLC’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-15,876
Closed -$90.2K – 1053
2026
Q2 		$90.2K Buy
+15,876
New +$128K 0.02% 851

Other funds holding LENZ

KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Kestra Private Wealth Services
Kestra Private Wealth Services Austin, Texas $9.37B AUM 22.72% 1-Year Est. Return
Harbor Capital Advisors
Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return
Indivisible Partners
Indivisible Partners Clearwater, Florida $2.18B AUM 33.61% 1-Year Est. Return
Kelleher Financial Advisors
Kelleher Financial Advisors New York $377M AUM 12.39% 1-Year Est. Return
Pinnacle Wealth Planning Services
Pinnacle Wealth Planning Services Mansfield, Ohio $1.03B AUM 22.32% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Abel Hall LLC's LENZ Position: Q3 2026 in Review

Abel Hall LLC sold out of LENZ Therapeutics (LENZ) in Q3 2026, closing a stake of 15,876 shares — an estimated $90.2K sold.

Abel Hall LLC first reported a position in LENZ in Q2 2026 and held it in 1 quarter. The position peaked at $90.2K in Q2 2026. 25 funds tracked by Wall St. Rank hold LENZ as of Q3 2026.

  • Abel Hall LLC reported no remaining LENZ Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Abel Hall LLC sold 15,876 LENZ Therapeutics shares in Q3 2026, an estimated $90.2K.
  • Abel Hall LLC first reported a position in LENZ Therapeutics in Q2 2026 and held it in 1 quarter.
  • Abel Hall LLC's LENZ Therapeutics position peaked at $90.2K in Q2 2026.
  • 25 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.